Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 22 | 2025 | 846 | 6.090 |
Why?
|
| Heart-Assist Devices | 12 | 2025 | 1085 | 3.260 |
Why?
|
| Heart Failure | 17 | 2025 | 2398 | 3.070 |
Why?
|
| Glomerular Filtration Rate | 10 | 2025 | 573 | 2.020 |
Why?
|
| Acute Kidney Injury | 7 | 2025 | 670 | 1.900 |
Why?
|
| Kidney | 10 | 2025 | 1338 | 1.830 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 2087 | 1.360 |
Why?
|
| Kidney Failure, Chronic | 5 | 2021 | 952 | 1.040 |
Why?
|
| Renal Replacement Therapy | 4 | 2021 | 158 | 1.020 |
Why?
|
| Plants | 2 | 2017 | 47 | 0.930 |
Why?
|
| Renal Dialysis | 8 | 2023 | 947 | 0.890 |
Why?
|
| Kidney Function Tests | 2 | 2022 | 138 | 0.850 |
Why?
|
| Creatinine | 5 | 2025 | 413 | 0.830 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2023 | 141 | 0.820 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 742 | 0.770 |
Why?
|
| Hematinics | 1 | 2023 | 59 | 0.770 |
Why?
|
| Hypernatremia | 1 | 2022 | 32 | 0.730 |
Why?
|
| Ficus | 1 | 2021 | 2 | 0.720 |
Why?
|
| Vascular Diseases | 1 | 2022 | 150 | 0.690 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2021 | 116 | 0.680 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 137 | 0.660 |
Why?
|
| Anemia | 2 | 2021 | 350 | 0.660 |
Why?
|
| Hospitalization | 6 | 2022 | 1897 | 0.660 |
Why?
|
| Humans | 47 | 2025 | 132055 | 0.650 |
Why?
|
| Nephrology | 1 | 2022 | 158 | 0.640 |
Why?
|
| Blood Volume | 1 | 2020 | 81 | 0.630 |
Why?
|
| Patient Care Management | 1 | 2020 | 66 | 0.630 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 154 | 0.600 |
Why?
|
| Blood Pressure | 3 | 2023 | 1402 | 0.600 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 509 | 0.590 |
Why?
|
| Kidney Tubules | 1 | 2018 | 74 | 0.590 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 463 | 0.580 |
Why?
|
| Heart Ventricles | 1 | 2023 | 785 | 0.570 |
Why?
|
| Serum Albumin | 1 | 2018 | 116 | 0.570 |
Why?
|
| Iron | 1 | 2020 | 302 | 0.540 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2022 | 304 | 0.540 |
Why?
|
| Echocardiography | 1 | 2023 | 1126 | 0.530 |
Why?
|
| Biomarkers | 5 | 2025 | 3403 | 0.530 |
Why?
|
| Radioactive Pollutants | 1 | 2017 | 1 | 0.530 |
Why?
|
| Hospital Mortality | 3 | 2019 | 1078 | 0.530 |
Why?
|
| Cystatin C | 3 | 2025 | 74 | 0.530 |
Why?
|
| Cohort Studies | 7 | 2023 | 5168 | 0.520 |
Why?
|
| Interleukin-1 | 1 | 2017 | 135 | 0.500 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 107 | 0.500 |
Why?
|
| Heart Transplantation | 2 | 2022 | 875 | 0.500 |
Why?
|
| Patient Readmission | 1 | 2020 | 425 | 0.490 |
Why?
|
| United States | 12 | 2025 | 11652 | 0.480 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 926 | 0.430 |
Why?
|
| Fertilizers | 1 | 2014 | 4 | 0.430 |
Why?
|
| Protective Agents | 1 | 2014 | 36 | 0.430 |
Why?
|
| Aged | 18 | 2025 | 21456 | 0.430 |
Why?
|
| Soil Pollutants | 1 | 2014 | 13 | 0.430 |
Why?
|
| Depressive Disorder | 1 | 2017 | 481 | 0.420 |
Why?
|
| Metals, Heavy | 1 | 2014 | 23 | 0.420 |
Why?
|
| Phosphorus | 1 | 2014 | 61 | 0.420 |
Why?
|
| Middle Aged | 19 | 2025 | 28979 | 0.410 |
Why?
|
| Phosphates | 1 | 2014 | 114 | 0.410 |
Why?
|
| Plasma Exchange | 1 | 2014 | 88 | 0.410 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3129 | 0.400 |
Why?
|
| Retrospective Studies | 12 | 2024 | 17367 | 0.390 |
Why?
|
| Risk Factors | 9 | 2025 | 10936 | 0.380 |
Why?
|
| Adult | 12 | 2025 | 31557 | 0.380 |
Why?
|
| Atherosclerosis | 1 | 2020 | 1006 | 0.370 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 202 | 0.360 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2011 | 61 | 0.340 |
Why?
|
| Male | 22 | 2025 | 64944 | 0.340 |
Why?
|
| Nutritional Status | 1 | 2011 | 294 | 0.310 |
Why?
|
| Inflammation | 1 | 2017 | 1522 | 0.300 |
Why?
|
| Female | 21 | 2025 | 70691 | 0.300 |
Why?
|
| Depression | 1 | 2017 | 1350 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1307 | 0.290 |
Why?
|
| Prevalence | 5 | 2022 | 2662 | 0.280 |
Why?
|
| Prospective Studies | 5 | 2025 | 6556 | 0.270 |
Why?
|
| Survival Rate | 4 | 2021 | 2192 | 0.260 |
Why?
|
| Prognosis | 6 | 2021 | 5013 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2025 | 3727 | 0.260 |
Why?
|
| Biodegradation, Environmental | 2 | 2017 | 13 | 0.240 |
Why?
|
| Nutrition Surveys | 2 | 2025 | 314 | 0.240 |
Why?
|
| Endostatins | 1 | 2025 | 8 | 0.230 |
Why?
|
| Biological Transport | 2 | 2017 | 348 | 0.220 |
Why?
|
| Albuminuria | 1 | 2025 | 113 | 0.220 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 7125 | 0.220 |
Why?
|
| Delirium | 1 | 2025 | 61 | 0.220 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2024 | 15 | 0.220 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2024 | 17 | 0.220 |
Why?
|
| Quality of Life | 3 | 2022 | 2159 | 0.210 |
Why?
|
| Glucaric Acid | 1 | 2023 | 9 | 0.200 |
Why?
|
| Ferric Compounds | 1 | 2023 | 40 | 0.200 |
Why?
|
| Japan | 1 | 2023 | 155 | 0.200 |
Why?
|
| Treatment Outcome | 5 | 2023 | 13015 | 0.190 |
Why?
|
| Fibrosis | 1 | 2023 | 421 | 0.180 |
Why?
|
| Pacemaker, Artificial | 1 | 2024 | 188 | 0.180 |
Why?
|
| Incidence | 2 | 2020 | 3370 | 0.180 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2022 | 48 | 0.180 |
Why?
|
| Body Mass Index | 2 | 2022 | 1699 | 0.180 |
Why?
|
| Defibrillators, Implantable | 1 | 2024 | 204 | 0.180 |
Why?
|
| Isoquinolines | 1 | 2021 | 40 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1160 | 0.170 |
Why?
|
| Sodium | 1 | 2022 | 296 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 110 | 0.170 |
Why?
|
| Machine Learning | 1 | 2024 | 348 | 0.170 |
Why?
|
| Heart Valve Prosthesis | 1 | 2024 | 331 | 0.170 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 235 | 0.170 |
Why?
|
| Glycine | 1 | 2021 | 162 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 222 | 0.160 |
Why?
|
| Kidney Diseases | 1 | 2024 | 490 | 0.160 |
Why?
|
| Mitochondria | 1 | 2024 | 751 | 0.150 |
Why?
|
| Ezetimibe | 1 | 2019 | 94 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 3753 | 0.150 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 571 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 256 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2019 | 183 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 375 | 0.140 |
Why?
|
| Systole | 1 | 2018 | 205 | 0.140 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 106 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 116 | 0.130 |
Why?
|
| Soil Pollutants, Radioactive | 1 | 2017 | 4 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 482 | 0.130 |
Why?
|
| Reference Values | 1 | 2018 | 703 | 0.130 |
Why?
|
| Biological Availability | 1 | 2017 | 143 | 0.130 |
Why?
|
| Mortality | 1 | 2018 | 260 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 551 | 0.130 |
Why?
|
| Lipids | 1 | 2020 | 561 | 0.120 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 398 | 0.120 |
Why?
|
| Stroke | 1 | 2024 | 1082 | 0.120 |
Why?
|
| Logistic Models | 1 | 2021 | 1836 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1443 | 0.120 |
Why?
|
| Registries | 1 | 2022 | 1591 | 0.120 |
Why?
|
| Uromodulin | 1 | 2014 | 11 | 0.110 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 24 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5407 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2232 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2018 | 1571 | 0.110 |
Why?
|
| Rhizosphere | 1 | 2014 | 4 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1500 | 0.110 |
Why?
|
| Agriculture | 1 | 2014 | 32 | 0.110 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2013 | 30 | 0.100 |
Why?
|
| Soil | 1 | 2014 | 71 | 0.100 |
Why?
|
| Brain | 1 | 2025 | 3191 | 0.100 |
Why?
|
| Medicare | 3 | 2021 | 447 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 1460 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 231 | 0.090 |
Why?
|
| Vascular Calcification | 1 | 2012 | 71 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 2312 | 0.090 |
Why?
|
| Obesity | 1 | 2022 | 2397 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1417 | 0.080 |
Why?
|
| Nutritional Requirements | 1 | 2011 | 160 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 663 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 2137 | 0.080 |
Why?
|
| Linear Models | 1 | 2011 | 711 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 348 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2013 | 988 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2012 | 549 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 6442 | 0.060 |
Why?
|
| Preoperative Period | 1 | 2025 | 92 | 0.060 |
Why?
|
| Young Adult | 1 | 2019 | 9938 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 251 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 124 | 0.050 |
Why?
|
| Organ Size | 1 | 2025 | 447 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 3086 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2025 | 375 | 0.050 |
Why?
|
| Mathematical Concepts | 1 | 2021 | 7 | 0.040 |
Why?
|
| Adolescent | 1 | 2019 | 20530 | 0.040 |
Why?
|
| Ferritins | 1 | 2021 | 109 | 0.040 |
Why?
|
| Health Surveys | 1 | 2021 | 259 | 0.040 |
Why?
|
| Metformin | 1 | 2021 | 165 | 0.040 |
Why?
|
| Equipment Design | 1 | 2021 | 600 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 3632 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2000 | 183 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 252 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 1255 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 2163 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2000 | 548 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 507 | 0.030 |
Why?
|
| Critical Illness | 1 | 2020 | 617 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 94 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 153 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1610 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 3014 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 2952 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2000 | 55 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2000 | 113 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2000 | 195 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2000 | 536 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2000 | 861 | 0.010 |
Why?
|